Work

เฟโซลิเนแทนต์: ยากลุ่มใหม่ในการรักษาอาการร้อนวูบวาบในภาวะวัยหมดประจำเดือน

Year: 2025
Type: article
Abstract: Fezolinetant is the first and only currently approved neurokinin 3 (NK3) receptor antagonist by the U.S. FDA on May 12, 2023, for the treatment of moderate to severe vasomotor symptoms (hot flashes, including night sweats) associated with menopause. But it is the second nonhormonal drug approved by the U.S. FDA for this indication. Fezolinetant works by specifically binding to NK3 receptors in the hypothalamus and inhibiting the activities of NK3 receptors in the hypothalamus, which play a key role in the malfunction of the body’s internal thermostat, resulting in hot flashes on the trunk, face, arms, and legs, and night sweats. The U.S. FDA-approved dose of fezolinetant for the treatment of vasomotor symptoms associated with menopause is one tablet (45 mg) taken once daily. A systematic review of the literature found that the drug is significantly more effective than placebo in reducing the frequency of vasomotor symptoms and has a good safety profile, with a very low or almost no incidence of liver enzyme elevations. Therefore, it is another additional option that is both effective and safe. However, there are still precautions to be taken when using it in patients with kidney and liver disease, and blood values should be monitored during treatment.
Language: Thai
Field: Medicine
Open Access status: diamond
OpenAlex ID: W7219315652
FWCI:
Cites: 9
Cited by:
Related to: 10